

REMARKS


Claims 1-9, 11-13, 15-18, 20-23, 27 and 29 are pending in the application.

Claims 11 and 12 have been rejected under 35 USC 112, first paragraph, by the Examiner as being vague and indefinite in that they are dependent upon a cancelled claim. The claims have been amended to depend from a pending claim, rendering this rejection of the claims moot.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: May 7, 2009
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988